Cellular metabolic changes in lymphocytes co-cultured with glioma explants were assessed by FLIM in response to immunotherapy with anti-PD-1/PD-L1 and anti-CTLA-4 antibodies and their combination. The gene discussed is CTLA4; the disease is central nervous system cancer.